title: Bone Histology of Two Cases with Osteomalacia Related to Low-dose Adefovir.
abstract: We performed a bone histomorphometric analysis in two patients demonstrating Fanconi syndrome with hypophosphatemia, adefovir-related bone disease and chronic hepatitis B infection. Both patients had osteomalacia, but showed two different histological patterns. The osteoid volume of the patient without risedronate increased with [(osteoid volume/ bone volume)×100=18.6%]. However, the osteoid volume of the patient receiving risedronate without vitamin D analogue showed a greater increase of 53.8%. In both patients bone pain and hypophosphatemia subsided soon after the discontinuation of adefovir and the administration of phosphate derivative. These findings show that bisphosphonate may worsen this disease when this drug is administered without a vitamin D analogue.
authors.affiliation: Nephrology Center, Toranomon Hospital, Japan.
authors.forename: Rikako
authors.initials: R
authors.lastname: Hiramatsu
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Ubara
authors.forename: Naoki
authors.initials: N
authors.lastname: Sawa
authors.forename: Eiko
authors.initials: E
authors.lastname: Hasegawa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kawada
authors.forename: Aya
authors.initials: A
authors.lastname: Imafuku
authors.forename: Keiichi
authors.initials: K
authors.lastname: Sumida
authors.forename: Junichi
authors.initials: J
authors.lastname: Hoshino
authors.forename: Kenmei
authors.initials: K
authors.lastname: Takaichi
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D005198:Fanconi Syndrome / Q000150:complications; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy; D006801:Humans; D017674:Hypophosphatemia / Q000150:complications; D059352:Musculoskeletal Pain / Q000209:etiology / Q000473:pathology / Q000628:therapy; D063065:Organophosphonates / Q000009:adverse effects*; D010018:Osteomalacia / Q000139:chemically induced* / Q000473:pathology*; D000068296:Risedronic Acid / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D050071:Bone Density Conservation Agents; D063065:Organophosphonates; C053001:adefovir; D000225:Adenine; D000068296:Risedronic Acid